Anita Clayton, MD
Anita Clayton, MD, a professor in the Department of Psychiatry and Neurobehavioral Sciences, published a study in the American Journal of Psychiatry that was highlighted and reviewed by Psychiatric Times.
The study assessed the efficacy and safety of a 14-day treatment course of once-daily zuranolone 50 mg for the treatment of major depressive disorder. A randomized, double-blind, placebo-controlled phase 3 clinical trial was conducted from May 2020 to April 2021 at 39 sites across the United States.
The review in Psychiatric Times concluded that Zuranolone at 50 mg/day led to significant improvement in depressive symptoms at day 15 when compared with placebo. Improvements in depression and anxiety symptoms were sustained through day 42 for participants taking Zuranolone. Overall, Zuranolone was well tolerated when compared with placebo.
Filed Under: Media Highlights